JP2018526450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526450A5 JP2018526450A5 JP2018531280A JP2018531280A JP2018526450A5 JP 2018526450 A5 JP2018526450 A5 JP 2018526450A5 JP 2018531280 A JP2018531280 A JP 2018531280A JP 2018531280 A JP2018531280 A JP 2018531280A JP 2018526450 A5 JP2018526450 A5 JP 2018526450A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- promoter
- composition according
- early
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562215651P | 2015-09-08 | 2015-09-08 | |
| US62/215,651 | 2015-09-08 | ||
| PCT/KR2016/009866 WO2017043815A1 (en) | 2015-09-08 | 2016-09-02 | Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526450A JP2018526450A (ja) | 2018-09-13 |
| JP2018526450A5 true JP2018526450A5 (https=) | 2019-08-29 |
| JP6895968B2 JP6895968B2 (ja) | 2021-06-30 |
Family
ID=58240110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531280A Expired - Fee Related JP6895968B2 (ja) | 2015-09-08 | 2016-09-02 | サイトカインおよびカルボキシルエステラーゼを発現する腫瘍溶解性改変ワクシニアウイルス、および、その使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10646524B2 (https=) |
| EP (1) | EP3347460A4 (https=) |
| JP (1) | JP6895968B2 (https=) |
| KR (1) | KR102674362B1 (https=) |
| CN (1) | CN108350434B (https=) |
| AU (1) | AU2016320355B2 (https=) |
| CA (1) | CA2996120C (https=) |
| HK (1) | HK1255192A1 (https=) |
| WO (1) | WO2017043815A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| CN108025056B (zh) * | 2015-06-19 | 2022-01-14 | 新罗杰股份有限公司 | 用于病毒栓塞的组合物和方法 |
| JP7025339B2 (ja) | 2016-02-25 | 2022-02-24 | メモリアル スローン ケタリング キャンサー センター | 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス |
| CN109152827B (zh) | 2016-02-25 | 2023-07-21 | 纪念斯隆凯特琳癌症中心 | 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途 |
| EP3610870A4 (en) * | 2017-03-31 | 2020-12-09 | Ogata, Hisanobu | METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT |
| EP3621646A4 (en) | 2017-05-12 | 2021-06-02 | Memorial Sloan Kettering Cancer Center | VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY |
| CN109554353B (zh) * | 2017-09-26 | 2021-08-06 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| EP3973973A1 (en) | 2017-10-31 | 2022-03-30 | KaliVir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
| US11786569B2 (en) * | 2018-01-26 | 2023-10-17 | University of Pittsburgh—of the Commonwealth System of Higher Education | Expression of metabolic modulators in tumor microenvironment to improve tumor therapy |
| WO2020014543A2 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| BR112021004692A2 (pt) * | 2018-09-15 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | poxvírus recombinantes para imunoterapia de câncer |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CN113748124A (zh) | 2019-02-27 | 2021-12-03 | 阿克蒂姆治疗有限公司 | 工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌 |
| JP7625589B2 (ja) * | 2019-10-16 | 2025-02-03 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 改変細胞外エンベロープウイルス |
| CA3161450A1 (en) | 2019-11-12 | 2021-05-20 | Actym Therapeutics, Inc. | Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products |
| CA3163805A1 (en) * | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| WO2022036159A2 (en) | 2020-08-12 | 2022-02-17 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
| US20240102912A1 (en) * | 2020-11-09 | 2024-03-28 | Thrive Bioscience, Inc. | Plaque counting assay method |
| CA3197371A1 (en) | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| EP4329786A4 (en) | 2021-04-30 | 2024-12-11 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| CA3235418A1 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100872884B1 (ko) * | 2000-03-24 | 2008-12-10 | 바이오스피어 메디칼 인코포레이티드 | 능동 색전화용 미소구 |
| EP2269619A1 (en) * | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | Methods and compositions concerning poxviruses and cancer |
| KR101772375B1 (ko) * | 2005-09-07 | 2017-08-29 | 신라젠(주) | Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법 |
| KR101942237B1 (ko) * | 2011-01-04 | 2019-01-25 | 신라젠(주) | 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산 |
| DK3036329T3 (da) * | 2013-08-22 | 2021-01-11 | Univ Pittsburgh Commonwealth Sys Higher Education | Immunonkolytiske terapier |
-
2016
- 2016-09-02 HK HK18114315.9A patent/HK1255192A1/zh unknown
- 2016-09-02 WO PCT/KR2016/009866 patent/WO2017043815A1/en not_active Ceased
- 2016-09-02 KR KR1020187009770A patent/KR102674362B1/ko active Active
- 2016-09-02 US US15/758,689 patent/US10646524B2/en active Active
- 2016-09-02 EP EP16844635.9A patent/EP3347460A4/en not_active Withdrawn
- 2016-09-02 CA CA2996120A patent/CA2996120C/en active Active
- 2016-09-02 AU AU2016320355A patent/AU2016320355B2/en not_active Ceased
- 2016-09-02 CN CN201680064990.2A patent/CN108350434B/zh active Active
- 2016-09-02 JP JP2018531280A patent/JP6895968B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526450A5 (https=) | ||
| Park et al. | Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer | |
| Khosravi et al. | Immunologic tumor microenvironment modulators for turning cold tumors hot | |
| Shen et al. | Persistent cancer cells: the deadly survivors | |
| Buqué et al. | Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer | |
| Vilgelm et al. | Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy | |
| Takeda et al. | A TLR3-specific adjuvant relieves innate resistance to PD-L1 blockade without cytokine toxicity in tumor vaccine immunotherapy | |
| JP6949131B2 (ja) | 治療用ｒｎａ | |
| Fridlender et al. | Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms | |
| Cui et al. | Generation of effector CD8+ T cells and their conversion to memory T cells | |
| Vacchelli et al. | Trial watch: immunostimulatory cytokines | |
| Hashimoto et al. | Type I IFN gene delivery suppresses regulatory T cells within tumors | |
| Di Carlo et al. | Depletion of slow-cycling PDGFRα+ ADAM12+ mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis | |
| CN114729358A (zh) | 涉及miRNA-193a的新疗法 | |
| JP2022524391A (ja) | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 | |
| Malhotra et al. | Oncolytic viruses and cancer immunotherapy | |
| WO2018228538A1 (zh) | 重组单纯疱疹病毒及其制备方法和应用 | |
| Perales-Puchalt et al. | IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment | |
| Ma et al. | High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment | |
| Du et al. | Therapeutic potential of targeting stromal crosstalk-mediated immune suppression in pancreatic cancer | |
| JP2019532047A (ja) | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ | |
| Sutanto et al. | Th17 cells in cancer: plasticity‐driven immunopathology and therapeutic opportunity | |
| Guo et al. | In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence | |
| He et al. | Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy | |
| Shi et al. | Ultrasound‑targeted microbubble destruction‑mediated Foxp3 knockdown may suppress the tumor growth of HCC mice by relieving immunosuppressive Tregs function |